(via TheNewswire)

Vancouver, British Columbia – TheNewswire - December 12, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “ Company ” or “ MindBio ”), a biotechnology company that conducts clinical health research and has developed prediction tools for drug and alcohol intoxication detection, is pleased to announce it has closed its non-brokered private placement (the “ Offering ”) for gross proceeds of $1,100,000.

In connection with closing of the Offering, the Company issued 2,070,000 units (each, an “ AI Unit ”) at a price of $0.40 per AI Unit for gross proceeds of $828,000 pursuant to the accredited investor exemption (the “ Accredited Investor Exemption ”) under Section 2.3 of National Instrument 45-106 - Prospectus Exemptions (“ NI 45-106 ”).  The Company also issued 680,000 units (each, a “ LIFE Unit ”) at a price of $0.40 per LIFE Unit for gross proceeds of up to $272,000 pursuant to the listed issuer financing exemption under Part 5A of NI- 45-106 (the “ Listed Issuer Financing Exemption ”).

Each AI Unit consists of one common share of the Company (each, a “ Share ”) and one share purchase warrant (each, a “ Warrant ”). Each Warrant entitles the holder to acquire an additional common share of the Company at a price of $0.70 until December 12, 2028, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days. Each LIFE Unit consists of one Share and one-half-of-one Warrant.

The Company intends to use the net proceeds from the Offering to advance development of its prediction technologies in drug and alcohol intoxication detection for consumer and enterprise utilisation, and for general working capital purposes

In connection with completion of the Offering, the Company paid $72,120 and issued 162,100 Warrants to certain arms-length parties who introduced subscribers to the Offering.  All securities issued in connection with the Accredited Investor Exemption are subject to restrictions on resale until April 13, 2026 in accordance with applicable securities laws.  All securities issued in connection with the Listed Issuer Financing Exemption are not subject to a hold period.

In connection with completion of the Offering, Company issued more than one-hundred percent of its existing share capital.  As a result, the policies of the Canadian Securities Exchange required the Company to obtain shareholder approval for the Offering.  The Company obtained shareholder approval by obtaining the written-consent of the majority of the outstanding Shares.

For further information, please contact:

Justin Hanka, Chief Executive Officer

61 433140886

justin@mindbiotherapeutics.com

About MindBio Therapeutics

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6) is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia, that for several years has been conducting clinical trials and is focused on developing novel treatments for mental health disorders and health prediction technologies using AI and machine learning.

Cautionary Note Concerning Forward-Looking Statements:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release.  All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2025 TheNewswire - All rights reserved.